The plasma peptides of breast versus ovarian cancer

BACKGROUND: There is a need to demonstrate a proof of principle that proteomics has the capacity to analyze plasma from breast cancer versus other diseases and controls in a multisite clinical trial design. The peptides or proteins that show a high observation frequency, and/or precursor intensity,...

Descripción completa

Detalles Bibliográficos
Autores principales: Dufresne, Jaimie, Bowden, Pete, Thavarajah, Thanusi, Florentinus-Mefailoski, Angelique, Chen, Zhuo Zhen, Tucholska, Monika, Norzin, Tenzin, Ho, Margaret Truc, Phan, Morla, Mohamed, Nargiz, Ravandi, Amir, Stanton, Eric, Slutsky, Arthur S., dos Santos, Claudia C., Romaschin, Alexander, Marshall, John C., Addison, Christina, Malone, Shawn, Heyland, Daren, Scheltens, Philip, Killestein, Joep, Teunissen, Charlotte, Diamandis, Eleftherios P., Siu, K. W. M., Marshall, John G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6927194/
https://www.ncbi.nlm.nih.gov/pubmed/31889940
http://dx.doi.org/10.1186/s12014-019-9262-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6927194/
https://www.ncbi.nlm.nih.gov/pubmed/31889940
http://dx.doi.org/10.1186/s12014-019-9262-0

Ejemplares similares